THERAPY DOSSIER · th-5d048fde8cde

ISO-1 ((S,R)-3-(4-hydroxyphenyl)-4,5-dihydro-5-isoxazole acetic methyl ester)

Drug

Evidence & regulatory context

Mechanism: Not recorded
Target: Not recorded
Injury models: Chemical/toxin
Reported indication: Not recorded
First approval: Not recorded
Development stage: Not recorded
ChEMBL record: Not recorded
ChEMBL max phase: Not recorded
Synonyms: Not recorded
Note: Not recorded

Clinical trials 0

0 linked trials carry an injury-indication flag. These flags support record-level exploration and sit alongside the stringent aggregate counts described in Methods.

No linked human trial in this dataset.

Preclinical evidence 1

1 studies reported at therapy level; 1 evidence entries itemised.

PMID 32683302 ↗2020Reported benefit

Inhibition of macrophage migration inhibitory factor prevents thyroid dysfunction in pregnant rats with acute pancreatitis.

RatChemical/toxinSprague-DawleyFemale (pregnant)Intraperitoneal30 minutes before model establishment (pretreatment)

Model: Acute pancreatitis in pregnancy induced by retrograde injection of sodium taurocholate

Thyroid injury occurred in acute pancreatitis in pregnancy and was attenuated by ISO-1 pretreatment, which reduced MIF expression, attenuated CD68, CD3 and ICAM-1 activation and improved oxidative stress status in maternal thyroid tissue.

Extraction: extract · Supplied extraction confidence: 0.6. Machine-extracted fields require source verification.

Loading the evidence…